Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

ICG- Livertest Versus New Biomarkers as Prognostic Markers in Critically Ill ICG- Livertest Versus New Biomarkers as Prognostic Markers in Critically Ill ((Greenpep))

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2010 by University of Zurich.
Recruitment status was  Recruiting
Intuitive Surgical
Information provided by:
University of Zurich Identifier:
First received: August 23, 2010
Last updated: March 15, 2011
Last verified: August 2010

ICG- Leberfunktionstest versus "neue" Biomarker als prognostischer Marker bei intensivmedizischen Patienten

Condition Intervention Phase
Critically Ill Patients
Procedure: Observational
Phase 4

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: ICG- Livertest Versus New Biomarkers as Prognostic Markers in Critically Ill

Further study details as provided by University of Zurich:

Estimated Enrollment: 100
Study Start Date: May 2010
Estimated Study Completion Date: May 2011
Groups/Cohorts Assigned Interventions
ICU patients
Admitted patients to the ICU
Procedure: Observational
Blood draw


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Admitted ICU Patients


Inclusion criteria: Gruppe 1:

  • Intensiv-Patienten mit Verbrennungen > 10% der Körperoberfläche
  • Alter > 18

Gruppe 2:

  • Intensivpatienten nach grossen chirurgischen Eingriffen
  • Alter > 18

Gruppe 3:

  • Polytraumatisierte, intensivpflichtige Patienten
  • Alter > 18

Exclusion criteria: • Alter < 18

  • Schwangerschaft
  • Einschluss in eine andere Studie
  • Moribunde Patienten
  • Patienten, die kein Deutsch verstehen
  • Jodunverträglichkeit
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01317381

Contact: 01 Studienregister MasterAdmins +41 (0)44 255 11 11

Zurich, Switzerland
Sponsors and Collaborators
University of Zurich
Intuitive Surgical
Study Director: 01 Studienregister MasterAdmins UniversitaetsSpital Zuerich
  More Information

No publications provided

Responsible Party: Béchir Markus, PI, CIM Identifier: NCT01317381     History of Changes
Other Study ID Numbers: Version 2.0. 08.12.2
Study First Received: August 23, 2010
Last Updated: March 15, 2011
Health Authority: Switzerland: UZurich

Additional relevant MeSH terms:
Critical Illness
Disease Attributes
Pathologic Processes processed this record on November 24, 2014